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Abstract
Background: A discrete sub-group of iatrogenically-acquired hepatitis C virus (HCV)-infected
individuals exists in the Irish population on whom limited current research data is available. The
aim of this study was to establish a current profile of the socio-demographic and clinical
characteristics of the Irish iatrogenic hepatitis C population and to determine factors predicting
symptoms experienced.
Methods:  An anonymous, national, cross-sectional survey was conducted to explore this
populations' self-reported health and social attributes. Data were collected on 290 respondents.
Results: Mean time since infection was 26 years. Eighty-four percent (n = 237) of respondents
were female (mean age = 55.9 ± 9.6 years). Hepatic and extra-hepatic symptoms were common
(62% and 99% respectively). Fatigue and pain were frequent complaints while 89% reported
diagnosed co-morbid disease. On logistic regression, female gender, age and co-morbid disease
emerged as independent predictors of self-reported symptoms.
Conclusion: This study describes the current status of the iatrogenically infected patient cohort
in Ireland, adding to existing knowledge regarding the clinical course and consequences of HCV
infection. Changing healthcare needs were shown by comparison with earlier surveys in this same
population, in terms of disease progression, development of co-morbid disease and ageing.
Background
Hepatitis C is a major public health problem. In 2000 the
WHO calculated that there were more than 170 million
chronic carriers worldwide (3% of world population)
with 3-4 million persons infected each year [1]. The late
effects of HCV infection include cirrhosis and hepatocel-
lular carcinoma, with reports that 27% and 25% of HCV
infected people progress to these respectively [2]. Hepati-
tis C is predominantly transmitted by means of exposure
to infected blood products and most new cases are related
to intravenous drug use (IVDU) [3].
Complete figures for the prevalence of HCV infection in
Ireland are not available [4], but annual incidence is now
being recorded with 1,572 new cases reported in 2007 [5].
In Ireland today new cases of hepatitis C may be the result
of HCV transmission through any of the recognised infec-
tion routes (62% of those recorded in 2007 were related
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to IVDU [6] (63% of whom were male [5])). A discrete
sub-group of people infected through transfusion with
contaminated blood products however exists in the Irish
HCV population. The National Hepatitis C Database
recently reported that, during the period 1970-1994, over
1600 individuals have been infected with HCV through
this mechanism, including people with haemophilia, kid-
ney disease and recipients of infected anti-D serum and
blood transfusions [7].
In Ireland, epidemiologic evaluation identified a single
HCV-infected individual as the source of virally contami-
nated anti-D administered to thousands of rhesus nega-
tive women during 1977 and 1978 [8]. This discovery
provoked a health care crisis for the blood transfusion
services and led to the establishment of a national screen-
ing programme in February 1994. In 1997 the Tribunal of
Inquiry into the Blood Transfusion Service Board (BTSB),
found that the primary cause of contamination of anti-D
with HCV was a breach of the BTSB's own standards for
donor selection and procedures [9]. A "targeted lookback"
and subsequently an "optional" screening programme
was then introduced for transfusion recipients in 1995
which identified a transfusion component and coagula-
tion factor transmitted hepatitis C infection [10]. The Irish
iatrogenic HCV cohort thus represents a homogeneous
group with a common infection source and ethnic origin.
Female predominance and a mean age at infection of 43-
46 years are additional unique attributes of this subsec-
tion of the Irish HCV population [8,11,12].
Hepatitis C incurs considerable social, physical and men-
tal health needs in those living with the disease [13,14]. In
addition to hepatic disease and its associated symptoms
which are well described [15-17] there are important
extra-hepatic manifestations [16] which cause significant
morbidity and impairment. Indeed it is these extra-
hepatic manifestations which dominate the symptoma-
tology of the condition and impair quality of life [16].
Extra-hepatic manifestations of HCV may involve multi-
ple body systems [18] however there is a preponderance
of rheumatic (arthralgia, myalgia, parasthesia) and cuta-
neomucous (pruritis, sicca syndrome, Raynaud's phe-
nomenon) symptoms [16]. Cacoub et al. [19] reported
that the most frequent extra-hepatic manifestations of
HCV were general symptoms (arthralgia, myalgia and par-
asthesia), however these were shown to be independently
associated with other extra-hepatic manifestations such as
vasculitis, purpura, psoriasis and abnormal creatinine lev-
els. Age, female sex and extensive liver fibrosis are
reported as the most frequent risk factors for the presence
of clinical and biologic extra-hepatic manifestations [19].
Co-morbid disease (e.g., obesity, diabetes, depression) is
emerging as an important and relevant factor in HCV pro-
gression, symptom experience and general well-being [20-
22]. Painful medical co-morbidities (e.g., arthritis) and
depressed mood requiring treatment have been associated
with greater levels of disability [20,23,24].
Much research has been done internationally in the hepa-
titis C population predominantly investigating the effec-
tiveness of different therapies [25-28], quality of life issues
[29-31], clinical symptoms [21,32,33], and prognosis
[8,34]. Given the availability of the unique homogeneous
cohort of iatrogenically infected individuals, research in
Ireland has focused mainly on the genetic and biomolecu-
lar aspect of the condition [35-37]. Some research has
examined the clinical symptoms and psychological
aspects of the disease [8,11,12,24,38-41]. Given that there
is a long latent period between HCV exposure and the
emergence of chronic liver disease (at least 2 decades
[17]), the importance of longitudinal follow-up has been
acknowledged. The National Hepatitis C Database was
created to gather information on this group of iatrogeni-
cally infected patients on an ongoing basis and it issued a
report in 2007 based on data collected in 2005 and 2006
from medical chart reviews [7].
The circumstances surrounding the infection of members
of the Irish population with contaminated blood and
blood products renders this group a unique cohort for
study. This, combined with the limited current research in
the Irish cohort in terms of health and social factors high-
lights a deficit in the literature. The current study did not
seek to duplicate data in the National Hepatitis C Data-
base but sought to bring a more personal perspective of
transfusion-related hepatitis C through the use of self-
report data.
Aim
The primary aim of this study was to describe the self-
reported health and social attributes of patients with past
or current exposure to iatrogenically transmitted hepatitis
C infection in the Irish population. The specific aims
addressed were:
1. To describe the socio-demographic characteristics of
the iatrogenic hepatitis C population in Ireland
approximately 30 years after the first recorded con-
tamination
2. To establish the prevalence of co-morbid conditions
in the group
3. To explore self-reported clinical manifestations of
the disease
4. To explore factors predicting the most prevalent
symptoms in this cohort.BMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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Methods
Design
An anonymous, national, cross-sectional survey of
patients with iatrogenic hepatitis C infection was under-
taken, using a self-completed postal questionnaire. Partic-
ipants were recruited during the period from November
2005 to March 2006.
Study Population
Adult individuals aged 18 years and older, who contracted
hepatitis C through contaminated, state-provided, blood
products, were eligible for inclusion. In the absence of a
complete national database at the time of data collection,
the membership lists of the four main patient advocacy
groups in the Republic of Ireland were selected as the
most complete sampling frame, representing people with
declared iatrogenic HCV infection. A population of one
thousand and forty five was identified. Patients thus could
be classified into: (i) anti-D, (ii) blood transfusion, (iii)
haemophilia and (iv) kidney disease exposure groups.
Seventy-two percent were members of Positive Action,
24% from Transfusion Positive, 2% were members of the
Irish Kidney Association and 2% were from the Irish Hae-
mophilia Society.
Questionnaire
A customised survey using closed and open-ended ques-
tions was prepared. The process for questionnaire devel-
opment followed recommended guidelines for survey
construction [42] and involved consultation with the
patient advocacy groups and a panel of experts (health
professionals and patients) thus ensuring that acceptabil-
ity and content validity of the questionnaire were assured.
Data were collected on socio-demographic variables (age,
gender, marital status, family circumstances and employ-
ment status) in addition to clinical history and symptoms
(co-morbidity, date of infection, date of diagnosis, current
antiviral therapy, symptoms (including site of pain if rel-
evant), and respective healthcare management). Socio-
demographic and employment-related questions were
modelled on the labour force and national household sur-
veys [43,44]. Clinical and symptom-related data were
derived from self-report on customised questions based
on clinical knowledge of hepatitis C and previous pub-
lished research [15,19,45,46]. The burden of co-morbid-
ity was measured using both a simple count of co-
morbidity and the Charlson Co-morbidity Index (CCI)
[47]. The CCI is a weighted index that takes into account
the number and seriousness of co-morbid disease, with a
higher number indicating more serious burden.
Procedure
Ethical approval was granted by the local Regional Hospi-
tal Ethics Committee. Confidentiality issues precluded
access by the research team to patients and their health
records therefore the assistance of the four relevant patient
advocacy groups was sought. Questionnaires were for-
warded to the subjects by the advocacy groups accompa-
nied by an information leaflet, a cover letter and a
stamped addressed envelope. Reminder letters were for-
warded to all recipients 3 weeks after the initial posting.
Consent to participate was implied by means of reply and
the respondent remained anonymous at all times.
Returned data were transcribed on to a computerised data
collection sheet which was stored securely. Colour coding
of questionnaires allowed anonymous responses to be
distinguished by patient group.
Analysis
Data were analysed using SPSS (Statistical Package for the
Social Sciences) version 12.0.1. Quantitative data were
summarised using descriptive statistics. Relationships
between variables were explored using Chi Square (2)
and Fishers tests for categorical data. Independent t tests
and one way ANOVA were used for ratio and interval data.
Categorical and continuous data were re-categorised and
recoded as appropriate. The International Labour Office
(ILO) criteria [44] were applied to determine the number
inactive in the labour force, the number of active labour
force participants and employment rates. The ILO calcu-
lates employment rates by expressing the number
employed as a percentage of those active (employed and
unemployed) in the labour force. Use of this method
facilitated direct comparison with national statistics, thus
permitting the effects of HCV to be interpreted with refer-
ence to general Irish population norms. All symptoms
reported by this population were perceived as being asso-
ciated with hepatitis C in the absence of another definitive
cause. Symptoms were categorised according to body
structure involvement. Those relating to hepato-gastro-
intestinal origins were termed hepatic and those relating
to other structures were classified as extra-hepatic. Calcu-
lations for measures of disease duration and time elapsed
since diagnosis, were made based on subtraction of the
stated year from January 1st 2006 (mid-point of data col-
lection period). Multivariate binary logistic regression
analysis was then conducted on these categorical variables
using a standard enter method to determine independent
predictors of the most commonly identified symptom
clusters which emerged. Findings of univariate analysis
were used to build the regression models, commonly
associated factors with these symptoms as reported in the
literature were also considered to inform the content of
the regression model. Haemophilia and mood disorders,
relevant medical conditions to the study cohort were
included as separate entities in the regression models,
given that they were not accounted for in the calculation
of the CCI [47] score. For significance level testing the p
value was set at p < 0.05. Ninety-five percent confidence
intervals for proportions and means were calculated usingBMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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methods outlined by Altman et al. [48] and Confidence
Interval Analysis Software version 2.1.2. [49].
Results
Sample Characteristics
In total, 290 (28%) questionnaires were returned.
Responses were received from members of all the patient
advocacy groups (Figure 1).
Socio-demographic Features
The main socio-demographic attributes for the total group
and each of the sub-groups are listed in table 1. Of the
total respondents 44 (16%) were male and 237 (84%)
were female with a mean age of 55.9 ± 9.6 years, ranging
from 20-80 years (median = 56 years). Twenty four out of
the 32 counties in the island of Ireland were represented
in the responses, with the highest response rate coming
from Dublin with 35% (n = 83) of replies. Approximately
99% of the sample population were of Irish nationality.
Further analysis of these findings found that females were
older, with a mean age of 56.9 ± 8.3 years by comparison
with 50.7 ± 13.5 years in males (t = 3.0, df = 49.3, 95% CI
= 2.0-10.5, p = 0.004). Only 42% of the cohort was eligi-
ble to be active participants in the labour force as defined
by the International Labour Office (ILO) Classification,
the other 58% being retired, working in the home or stu-
dents. Of the ninety-five eligible to work only 38 (40%)
were in employment, of whom 59% (n = 22) were female.
Permanent sickness or disability was cited by 52 individu-
als (91%) of the unemployed cohort as a reason for
unemployment.
Clinical Features
The mean time since diagnosis was 11.4 ± 3.6 years
(median 12, range 3-29 years) with a mean time since
infection of 26.3 ± 5.4 years (median 29, range 10-44
years) for the total group. Details of virus status and dura-
tion of infection are summarised in table 2. Over 43% (n
= 125) of the total sample (n = 290) were virus (PCR) pos-
itive (i.e., had evidence of current infection). The figures
quoted in table 2 excluded missing data. Of those who
were virus (PCR) negative (evidence of resolved infection)
(n = 61), 55.7% (n = 34) were virus negative following
antiviral treatment. One percent (n = 3) of respondents
reported undergoing antiviral treatment for hepatitis C at
the time of the survey. Interestingly the majority of the
Patient Group Representation Figure 1
Patient Group Representation.
2% 5%
57%
36%
Positive Action (n=165)
Transfusion Positive (n=104)
Irish Haemophilia Society (n=16)
Irish Kidney Association (n=5)
Table 1: Iatrogenic Hepatitis C - Socio-demographic Features.
Variable Total
(n = 290)
Positive Action
(n = 165)
Transfusion Positive
(n = 104)
Irish Haemophilia
Society
(n = 16)
Irish Kidney
Association
(n = 5)
Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd)
Age - (years) 55.9 (9.6) 55.8 (6.8) 57.9 (11.8) 46.2 (12.8) 52.2 (8.0)
Gender (n = 281) n(%)a n(%)a n(%)a n(%)a n(%)a
Male 44 (16) 0 ( 0) 27 (27) 15 (94) 2 ( 40)
Female 237 (84) 161 (100) 72 (73) 1 ( 6) 3 ( 60)
Education(n = 271)
Primary 59 (22) 32 ( 21) 25 (26) 2 (13) 0 ( 0)
Secondary 143 (53) 86 ( 55) 47 (49) 6 (40) 4 ( 80)
Tertiary 69 (25) 37 ( 24) 24 (25) 7 (47) 1 ( 20)
Marital Status (n = 279)
Married 215 (77) 132 ( 83) 72 (74) 9 (56) 2 ( 40)
Not Married 64 (23) 28 ( 17) 26 (26) 7 (44) 3 ( 60)
Dependents (n = 263)
Yes 103 (39) 65 ( 43) 32 (35) 5 (33) 1 ( 20)
No 160 (61) 86 ( 57) 60 (65) 10 (67) 4 ( 80)
Employment Status
(n = 95)
Employed 38 (40) 17 ( 35) 13 (38) 8 (80) 0 ( 0)
Unemployed 57 (60) 31 ( 65) 21 (62) 2 (20) 3 (100)
a Where missing responses, percentages were calculated out of available responsesBMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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respondents were unsure of their genotype. Over 62% (n
= 180) either left the question unanswered or stated that
they did not know what their genotype was. Of those
respondents who were aware of their genotype (n = 110),
genotype 1, 1a and 1b accounted for 71% (n = 78), 15%
(n = 17) had genotype 2, while 12% (n = 13) had geno-
type 3. The remaining 2% (n = 2) of respondents reported
types 4 and 5.
Fifty-five percent (n = 160) of respondents had contracted
the virus through anti-D, 8% (n = 22) via blood products
and 33% (n = 96) by blood transfusion. The remaining
4% (n = 12) contracted the virus through alternative
means which included a combination of sources (e.g.,
anti-D and blood transfusion, blood products (i.e., no
conclusive source), blood products in a transplanted liver,
mother-to-child transmission (n = 2, 0.6%)).
Co-morbid Disease and Clinical Symptoms
Approximately 89% (n = 255) of the cohort reported at
least one concurrent medical condition. Table 2 provides
details of the most frequently specified disorders. Co-mor-
bid illness was reclassified using the CCI to facilitate fur-
ther analysis of the impact of co-morbid disease. The
mean score for the total group was 0.7 ± 1.0 with a range
of 0-6. The results of the CCI were then classified as per-
taining to low (scores 0-1) or moderate to high (scores 2-
6) co-morbidity levels. Eighty-four percent (n = 240) had
low levels of co-morbidity while the remaining 16% (n =
46) were classified in the moderate to high category.
Using a simple count method of co-morbidity measure-
ment, the median listed number of co-morbidities per
person was 2 and ranged from 0-9 (mean = 2.5 ± 1.8).
Self-report of symptoms highlighted important features of
the condition. Table 2 illustrates the most frequent symp-
toms cited. These symptoms were categorised according to
body structure involvement as hepatic and extra-hepatic
symptoms, but were not mutually exclusive (62% (n =
169) and 99% (n = 275) respectively). Cacoub et al. [19]
classified any symptoms involving joint, muscles and skin
as extra-hepatic clinical manifestations while Poynard et
al. [16] included fatigue among this group. The current
study further distinguished symptoms of more advanced
Table 2: Iatrogenic Hepatitis C - Clinical Features, Co-morbid Disease and Symptoms
Variable Total
(n = 290)
Positive Action
(n = 165)
Transfusion Positive
(n = 104)
Irish Haemophilia
Society
(n = 16)
Irish Kidney
Association
(n = 5)
Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd)
Duration of Infection 26.3 (5.4) 27.9 (3.9) 23.5 (6.5) 26.1 (5.4) 29.5 (3.5)
Time Since Diagnosis 11.4 (3.6) 11.9 (3.7) 10.5 (3.3) 13.6 (2.4) 9.3 (1.3)
n (%)a n (%)a n (%)a n (%)a n (%)a
Virus Status(n = 186)
PCR Positive 125 (67) 74 (76) 42 (55) 6 ( 60) 3 (100)
PCR Negative 61 (33) 23 (24) 34 (45) 4 ( 40) 0 ( 0)
Symptoms
Hepatic (n = 275) 169 (62) 95 ( 61) 63 (64) 6 ( 38) 5 (100)
Extra-hepatic (n = 278) 275 (99) 159 (100) 95 (97) 16 (100) 5 (100)
Fatigue (n = 274) 241 (88) 139 ( 90) 86 (88) 12 ( 75) 4 ( 80)
Pain (n = 252) 243 (96) 147 ( 97) 80 (95) 12 (100) 4 ( 80)
Sleep Disturbance (n = 274) 197 (72) 111 ( 72) 75 (77) 7 ( 44) 4 ( 80)
Itching (n = 274) 132 (48) 83 ( 54) 44 (45) 4 ( 25) 1 ( 20)
Abdominal Swelling 
(n = 273)
113 (41) 71 ( 46) 35 (36) 4 ( 25) 3 ( 60)
Co-morbid Disease
(n = 286)
Cardiovascular Disorder 144 (50) 88 ( 54) 48 (47) 3 ( 19) 5 (100)
Musculoskeletal Disorder 89 (31) 54 ( 33) 33 (32) 2 ( 13) 0 ( 0)
Mood Disorder 136 (48) 81 ( 50) 47 (46) 4 ( 25) 4 ( 80)
CCIb Category (n = 286)
Low 240 (84) 142 ( 88) 86 (84) 12 ( 75) 0 ( 0)
Moderate to high 46 (16) 20 ( 12) 17 (16) 4 ( 25) 5 (100)
Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd) Mean (Sd)
CCIb score 0.7 (1.0) 0.6 (0.8) 0.8 (1.1) 0.8 (1.5) 2.4 (0.9)
Number of Co-morbidities 
Listed
2.5 (1.8) 2.4 (1.7) 2.5 (1.9) 2.6 (2.2) 5.2 (1.9)
aWhere missing responses, percentages were calculated out of available responses
bCCI = Charlson Co-morbidity IndexBMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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disease such as disturbed sleep [50] or abnormal renal
function [51,52] as extra-hepatic. Analysis of these symp-
toms (Additional file 1) revealed that a greater proportion
of females had hepatic symptoms (p = 0.007) and extra-
hepatic symptoms (p = 0.004) than males. When the rela-
tionship with age was explored no significant association
was noted. Virus positivity also failed to demonstrate any
significant associations with either symptom. Moderate to
high co-morbidity as measured by the CCI was associated
with a higher prevalence of hepatic symptoms (p =
0.024). The presence of a mood disorder was significantly
associated with greater hepatic symptoms only (p 
0.001) while haemophilia was not significantly related to
the presence of either symptom cluster. Analysis of the
effects of the duration of infection on symptom preva-
lence revealed a significant association with longer dura-
tions of infection associated with the presence of extra-
hepatic symptoms (p = 0.005).
Pain and Fatigue
Pain and fatigue were examined further given that these
symptoms are frequently cited in the literature as being
the most common extra-hepatic symptoms of hepatitis C.
Both fatigue and pain were present in 88% (n = 241) and
96% (n = 243) of the sample. Further exploration of pain
and more specifically musculoskeletal pain (71%, n =
173) revealed multiple and varying sites of body pain.
Breakdown of the location of this symptom found the
most common sites were lower limb (73%), upper limb
(67%), back (62%) and neck (28%). Fifty-seven per cent
reported taking medication for this pain.
No significant relationship was found between presence
of pain and age-group. Gender analysis on the other hand,
showed that more females reported pain than males (p <
0.01). With regard to fatigue, there was a significant differ-
ence between age groups in prevalence rates for fatigue (p
< 0.01) and females were more likely than males to expe-
rience fatigue (p = 0.011) (Additional file 1). Virus status
was not significantly related to the presence of these
symptoms, while the presence of a mood disorder was
linked with symptoms of fatigue (p = 0.004). An associa-
tion was noted between the presence of pain and fatigue
though it did not reach statistical significance (2 = 5.2; df
= 1; p = 0.056, 95% CI = 0.7-26.3%).
Factors Predicting Symptoms
Standard enter logistic regression analysis was performed
for hepatic, extra-hepatic, pain and fatigue symptom cate-
gories to determine which factors were of clinical rele-
vance. All variables presented for univariate analysis were
entered into the multivariate analysis, Additional file 1
details each of the models. For hepatic symptoms; female
gender (p = 0.039, OR 3.7), mood disorder (p  0.001, OR
7.5) and moderate to high co-morbidity (p = 0.022, OR
3.7) emerged significant predictors of having hepatic
symptoms. When the duration of infection was removed
from the model age under 50 years was also associated
with the presence of hepatic symptoms (p = 0.024, OR
3.4). When the regression model was constructed for
extra-hepatic symptoms no factor emerged as a significant
independent predictor. Female gender and age group were
both significant for fatigue. The under 50 years group had
a higher odds (OR 19.1, p = 0.013) of reporting symptoms
of fatigue than the other 2 groups. For pain, female gender
was the sole significant predictor of this symptom in this
cohort.
Discussion
This study examined the main socio-demographic and
clinical features of an iatrogenically acquired Irish hepati-
tis C cohort. A response rate of 28% while low, given the
methodological limitations required by the patient advo-
cacy groups for this postal survey to ensure anonymity,
was considered a representative sample with nationwide
response. Lack of direct access to patient databases
affected the researchers control over recruitment of sub-
jects and the ability to follow-up non-responders. The
study cohort was subject to a gender and age bias given the
population under review, but was reflective of the recently
published report on the Irish iatrogenic HCV cohort from
the National Hepatitis C Database[7]. The low response
rate and the obvious gender imbalance however should
still be considered when interpreting the results of this
survey, in particular the regression analysis in view of the
predictive effects of female gender in symptom experi-
ence.
Restricted access to the patient cohort necessitated use of
self-report data, derived from both an open-ended and
checklist-type question, for describing morbidity and clin-
ical manifestations of disease. Medical chart or physician
evaluated morbidity is often seen as "gold standard" how-
ever there is a growing body of research for the utility of
self-reported data for predicting disability and survival
[53-56]. Given the nature of the data retrieved respondent
and recall bias were other factors to consider when inter-
preting the results presented. The absence of an age-
matched control group, to compare symptoms and co-
morbid disease prevalence, in a case-control design, lim-
ited the interpretation of results with regard to cause and
effect. However the selection of a single sample cross-sec-
tional method was justified in the planning stages of the
current study given that prior published research on this
area in general used this methodology. Only two studies
were identified by the researcher that compared symp-
toms experienced by controls with the HCV group. Seeff et
al. [57] showed significant greater prevalence of tiredness
(37% v 26%, p = 0.01) and anorexia (17% v 5%, p =
0.0003) in HCV. Meanwhile, Hoofnagle [15] in theirBMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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cohort (n = 108) when compared to healthy blood donors
demonstrated a striking similarity in prevalence rates for
fatigue (62% v 70%), however abdominal pain (31% v
17%), itching (32% v 21%), nausea (19% v 16%) and
dark urine (23% v 5%) were more common in HCV
patients.
As expected, the demographic profile reported shows age-
ing of the iatrogenic HCV cohort since previous studies in
the late 1990s and given the well publicised mechanism
of infection via anti-D, was dominated by middle-aged
females in keeping with the National Hepatitis C Data-
base findings [7]. These results are in stark contrast with
other international studies with mixed transmission
routes whose samples were younger and male dominated
[20,21,58]. Previous studies completed on the Irish
cohort of transfusion-associated hepatitis C [8,12,38,59]
correspond well in terms of age profile when the time
elapsed is taken into consideration. The unemployment
rate (60%, n = 57) was high in those who were eligible to
participate in the labour force by comparison to the gen-
eral Irish population average which was 4.2% [60]at the
time of the survey. Analysis of the reasons given for unem-
ployment status revealed that 91% (n = 52) (55% of eligi-
ble active labour force participants), were unable to work
due to permanent sickness or disability. This is particu-
larly high given that the general Irish population statistics
show that of the active labour force population with any
disability or with disability due to chronic illness only
15.3% and 11% were unemployed respectively [61].
Based on these figures unemployment for those citing per-
manent sickness or disability was considerably higher
among the iatrogenic HCV cohort than the general Irish
population (55% v 15.3% and 11%).
The uniqueness of this study cohort, made comparison
with results from other studies difficult due to mixed clin-
ical, social, geographic and ethnic variables of interna-
tional cohorts. Forty-three percent (n = 125) of the study
sample were virus positive, a lower proportion than
reported in previous studies of this Irish group, where
medical chart review was performed [8,12] although this
correlated well with the more recent data presented in the
baseline report of the HPSC [7]. However, 34 respondents
(11.7%) reported that they were now virus negative fol-
lowing treatment, bringing the historic virus positive pro-
file of the group into concurrence with original studies
where 55% of patients were virus positive [8]. The high
proportion of the study cohort infected through a single
source influenced the genotype profile reported (71%
genotype 1) however this was consistent with the
National Hepatitis C Database. Discrepancies noted
between the current survey respondents and previous
Irish iatrogenic cohorts [12,59] can be rationalised by vir-
tue of the inclusion of both genders and all modes of
infection. At the time of this study a mere 1% reported
undergoing current treatment for HCV. The limited num-
bers of respondents treated (12% of the study cohort) and
undergoing treatment may be indicative of limited treat-
ment efficacy especially given the high proportion of the
cohort with genotype 1 (most resistant to treatment) [62]
but also the mildness of the disease progression in this
population.
Approximately 99% (n = 275) of respondents had symp-
toms perceived as relating to their hepatitis C. This figure
was notably higher than that reported in Kenny-Walsh's
Irish study in 1999 [8] where 81% had symptoms.
Cacoub and colleagues [19] reported the presence of at
least one extra-hepatic manifestation in 74% of their
study participants. Extra-hepatic symptoms were more
prevalent (99%) in the current study than hepatic symp-
toms, which were reported in 62%. Differences in the lev-
els of symptoms recorded in the current study were also
noted when compared to the National Hepatitis C Data-
base. This may be related to their non-specific nature and
the different methods used to collate data. The National
Hepatitis C Database [7] examined extra-hepatic manifes-
tations in terms of biologically and clinically diagnosed
phenomena (10.2%). Meanwhile the current study find-
ings were based on self-reported symptomatology and not
definitive diagnoses. The most prevalent symptoms here
were fatigue and pain with 88% and 96% complaining of
these symptoms respectively whereas in the Kenny-Walsh
study of the anti-D cohort, 66% reported fatigue and 38%
arthralgia. Similarly lower rates of fatigue (33-39%) and
pain (23-25%) were reported in earlier studies in the Irish
iatrogenic HCV population by Barrett et al. [11] and
Coughlan et al. [12]. These high symptom prevalence
rates (extra-hepatic 99%; pain 96%; fatigue 88%) are
important to acknowledge as being open to possible
respondent bias. However, advancing age and longer
duration of infection at the time of the current study may
also explain this increase. The use of a medical chart
review in the National Hepatitis C Database [7] limited
comparisons with this report, although the recorded lev-
els of fatigue (30%) and arthralgia (24%) were substan-
tially lower than the data presented here.
Cacoub et al. [19] found that the most frequent risk fac-
tors for the presence of clinical and biologic extra-hepatic
manifestations were age, female gender and extensive liver
fibrosis. Further analysis on the effects of age, gender,
virus status and duration of infection on the presence of
symptoms in the current cohort found that female gender
was a significant predictor. Surprisingly no factor emerged
as independently predictive of the combined category of
extra-hepatic symptoms in this study. Closer examination
of the two most common extra-hepatic complaints,
fatigue and pain, revealed that female gender was a signif-BMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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icant factor in both of these symptoms while age was an
important predictor of fatigue only. Complaints of fatigue
were less likely in older individuals in contrast to the find-
ings of Cacoub et al. [19]. Virus status (chronic or self-lim-
ited infection) or duration of infection were not
associated with the presence of symptoms though lack of
knowledge of disease severity in this group limited further
comparison with Cacoub's study. The lack of association
of these clinical factors with pain and fatigue concurred
with the findings of Barkhuizen et al. [45], who found that
these symptoms while frequently present in patients with
chronic hepatitis C were unrelated to the severity of the
liver disease. The presence of symptoms in the absence of
organic disease for the virus negative group is an interest-
ing finding and concurred with earlier research in a simi-
lar cohort [11]. Symptoms in those with self-limited or
resolved HCV infection may be related to physical or psy-
chosocial influences associated with past infection with
HCV. This requires further investigation. However, it
should be noted that a high proportion (36%, n = 104) in
the present study cohort failed to report their current viral
status, therefore the relationship between symptoms and
virology must be interpreted with caution here. The high
levels of missing data may reflect a lack of knowledge in
the cohort or may be due to omission or respondent selec-
tion. Meanwhile, similar to fatigue, associations with
younger age were shown for the hepatic cluster of symp-
toms when duration of infection was removed from the
regression model. No research has been conducted to date
on factors predicting hepatic symptoms thus limiting
comparisons.
In the current study 89% of the sample had at least one
diagnosed medical condition. Recoding of the CCI illus-
trated that in the main the iatrogenic HCV cohort experi-
enced low levels of co-morbidity (84%). The most
frequent conditions reported were cardiovascular (50%),
mood-related (48%) and musculoskeletal (31%), in keep-
ing with other international studies [21,22,63]. The lim-
ited study in this area in the Irish cohort revealed some
interesting figures for comparison with previously pub-
lished data. When examining specific conditions, Kenny-
Walsh [8] found the level of cardiovascular disorders was
8% and psychological 7%. The presence of co-morbidity
has thus expanded vastly in this cohort. The presence of
co-morbid disease is important to the overall well-being
of this group as has been proven in previous studies, the
amelioration of which may lead to improved HRQoL [20-
22]. Reference figures for the National Hepatitis C Data-
base [7] showed an underreporting of some co-morbid
diseases e.g., depression (27%) by comparison with self-
reported data in the current study (43%). Missing data
and a lack of standardised medical record keeping across
the different hepatology units was cited as a possible
source of error in the National Hepatitis C Database hence
the findings of this study may present a more representa-
tive picture of co-morbidity in this HCV population. Psy-
chiatric illness as well as adversely effecting HRQoL, also
plays a role in treatment success, given the importance of
adherence to treatment which can be complicated by con-
ditions such as depression. Mood disturbance and moder-
ate to high co-morbidity was associated with hepatic
symptoms thus supporting the premise that co-morbid
disease is an important factor in health status for this
group. Depression has been associated with stigma, well-
being and adverse expectations of illness [24,40]. Dwight
et al. [23] examined the relationship of depressive symp-
toms to fatigue and functional disability. They found that
the severity of depressive symptoms highly correlated
with fatigue severity, functional disability and somatisa-
tion. Proactive management of depression has been advo-
cated to improve HRQoL and the efficacy of antiviral
therapy for hepatitis C [58]. Co-morbid mood distur-
bance did show a significant association with extra-
hepatic symptoms, fatigue in particular in this group
though it was not an independent predictor of these
symptoms. Further investigation and management of this
symptom and mood disorders are warranted in this
cohort given its' unclear patho-physiology and that
McDonald et al. [64] and Dwight et al. [23] reported that
fatigue was more closely related to psychopathology than
hepatic disease.
The unlikely association of younger age and symptoms
warranted further exploration of study findings. The hae-
mophilia group although younger was predominantly
male and had an equivalent duration of infection to the
other patient groups. The combination of male gender
and mean disease duration of 26 years could potentially
be associated with faster disease progression
[16,17,35,62,65,66] and hence higher symptom preva-
lence. Signs of decompensated liver disease include
fatigue [67] and thus more information on liver disease
severity would facilitate better interpretation of these
results. No significant difference was found however
between the groups in terms of symptom prevalence or
mood disturbance (unpublished findings) which is
important given that somatisation has been linked with
mood disturbance in other studies [23,24]. Mood disor-
ders were not associated with age (unpublished findings).
The generally older age profile of the cohort meant that a
significant proportion carried an additional disease bur-
den (advanced age was associated with co-morbid disease
p < 0.05). Those with renal disease and haemophilia had
a higher percentage of the moderate to high category of
co-morbid disease and this may have influenced study
findings. Disease labelling and awareness of diagnosis has
been associated with deficits in well-being [31]. The
longer duration of awareness of diagnosis in the haemo-
philia group may have affected the patients' perception ofBMC Public Health 2009, 9:323 http://www.biomedcentral.com/1471-2458/9/323
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symptoms. Indeed the complaints of fatigue and other
symptoms usually associated with an older population
may have been perceived more in the younger cohort
where these symptoms were seen as abnormal and this
may have affected the results [68].
Given the proven influence of viral and host factors in dis-
ease progression, the emerging role of co-morbidity in
fibrogenesis, as is true for diabetes [17,66,69,70], and the
need for these factors to be taken into consideration when
deciding on suitability for antiviral treatment [67,71] fur-
ther emphasises the need for implementing appropriate
management strategies. The median time to cirrhosis
development has been reported as 30 years [17], a time-
frame within which the majority of this group were
infected. With the development of cirrhosis, disease sever-
ity is progressing hence the need for effective interven-
tions to influence the modifiable factors for disease
progression such as weight, diet, alcohol consumption by
means of a health promotion and activity programme.
The high incidence of musculoskeletal and cardiovascular
disorders highlights a potential rehabilitation and health
promotion need in this cohort. A previous review into the
proposed benefits of exercise in chronic liver disease
found some support in the literature. It was suggested that
a structured exercise programme could be used to comple-
ment the medical management strategies for hepatitis C,
through the reduction of diabetes and cardiovascular risk,
prevention of obesity and management of fatigue as well
as musculoskeletal and neuropathic symptoms [72].
Conclusion
Socio-demographic and clinical data characteristics pre-
sented here provide additional data to that recorded in the
National Hepatitis C Database report, on an ageing iatro-
genically infected HCV cohort in Ireland, which has rele-
vance for future planning of hepatology services. The
growing disease burden of the Irish iatrogenic HCV cohort
represented here by comparison to previous research con-
ducted in this population emphasises the importance of
prospective follow-up to document the emerging symp-
toms and co-morbid disease and indeed the suitability of
this unique group for follow-up. Much has been written in
the literature about the effects of ageing on disease pro-
gression. International research has highlighted an
expected "age wave of disease burden" with chronic hep-
atitis C [67]. The advancing age and associated shift in co-
morbid disease prevalence identified here has important
implications for cirrhosis development and advancement
for this cohort. In addition to influencing liver disease
progression, these co-morbid diseases may also independ-
ently influence healthcare utilisation and QoL. The emer-
gence of high levels of disease-related symptoms is
another important factor to consider when planning
future health services for this cohort. Higher disease bur-
dens were identified in those under 50 years of age,
females and those with co-morbid physical and psycho-
logical conditions and thus strategies need to be devel-
oped to target these vulnerable sub-groups. Review of
existing and the development of new appropriate health
policies and management strategies for HCV are essential
to address the long-term care of this cohort and will
inform the health provision for HCV patients of all infec-
tion routes.
This study showed a growing healthcare burden reported
by HCV sufferers, emphasising the myriad of effects of the
HCV in terms of diffuse symptoms and associated co-mor-
bidity. The high prevalence and nature of the co-morbidi-
ties reported combined with the frequent complaints of
pain and fatigue, indicate the need for strategies which
focus more on physical health and health promotion.
Health service planners and practitioners need to target
and direct resources to the management of disease-related
symptoms and prevention of co-morbidity specifically,
thus addressing the additional healthcare needs more
effectively given the current limited antiviral treatment
success.
While the response rate was low, the study cohort was
nonetheless representative of the Irish iatrogenic HCV
population. The results presented provide data regarding
the evolving health and social circumstances of patients
with iatrogenically transmitted hepatitis C infection in Ire-
land, adding to existing knowledge regarding the clinical
course and consequences of this source of HCV infection
over time.
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